CLSD vs. ORMP, ANIX, BTAI, ALLK, PMVP, OPTN, CUE, IOBT, DMAC, and ETON
Should you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include Oramed Pharmaceuticals (ORMP), Anixa Biosciences (ANIX), BioXcel Therapeutics (BTAI), Allakos (ALLK), PMV Pharmaceuticals (PMVP), OptiNose (OPTN), Cue Biopharma (CUE), IO Biotech (IOBT), DiaMedica Therapeutics (DMAC), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical preparations" industry.
Oramed Pharmaceuticals (NASDAQ:ORMP) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.
Clearside Biomedical received 39 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. However, 74.82% of users gave Oramed Pharmaceuticals an outperform vote while only 67.17% of users gave Clearside Biomedical an outperform vote.
Oramed Pharmaceuticals has a net margin of 0.00% compared to Oramed Pharmaceuticals' net margin of -394.91%. Oramed Pharmaceuticals' return on equity of 0.00% beat Clearside Biomedical's return on equity.
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are owned by institutional investors. 12.0% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 9.8% of Clearside Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Oramed Pharmaceuticals has higher earnings, but lower revenue than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Oramed Pharmaceuticals has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.29, indicating that its stock price is 129% more volatile than the S&P 500.
Clearside Biomedical has a consensus target price of $4.75, indicating a potential upside of 274.02%. Given Oramed Pharmaceuticals' higher possible upside, analysts clearly believe Clearside Biomedical is more favorable than Oramed Pharmaceuticals.
In the previous week, Oramed Pharmaceuticals and Oramed Pharmaceuticals both had 2 articles in the media. Clearside Biomedical's average media sentiment score of 1.55 beat Oramed Pharmaceuticals' score of -0.50 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.
Summary
Oramed Pharmaceuticals beats Clearside Biomedical on 9 of the 16 factors compared between the two stocks.
Get Clearside Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLSD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clearside Biomedical Competitors List
Related Companies and Tools
